Cat. No.: HY-B0255

Adefovir dipivoxil

Name: Adefovir dipivoxil
Brand: MedChemExpress
SKU: HY-B0255
Price: 55.00 USD
Availability: InStock
Rating: 5 (2 reviews)

(Synonyms: GS 0840)

2 Cited Publications

Avis client

Based on 2 publication(s) in Google Scholar

Adefovir dipivoxil is an orally active adenosine analog and Adefovir prodrug. Adefovir dipivoxil inhibits DNA synthesis, activates the ATR signaling pathway, and disrupts the KCTD12-CDK1 interaction. Adefovir dipivoxil has antiviral activity against PRV, HBV, and orthopoxviruses. Adefovir dipivoxil has inhibitory effects on both lamivudine-resistant and wild-type strains. Adefovir dipivoxil has antitumor activity against lung and colon cancer.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté : 99.03%
CAS No.: 142340-99-6
Formule: C₂₀H₃₂N₅O₈P
Masse moléculaire:501.47

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Adefovir dipivoxil Chemical Structure

CAS No.: 142340-99-6

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (2)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole (4)
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Voir tous les produits spécifiques à Isoform HSV :

Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis :

Voir tous les produits spécifiques à Isoform ATM/ATR :

Voir tous les produits spécifiques à Isoform CDK :

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	CC₅₀	0.74 μM Compound: 15, Bis(POM)-PMEA	Cytotoxicity against CEM/O cells Cytotoxicity against CEM/O cells	[PMID: 16335932]
CCRF-CEM	CC₅₀	1.6 μM Compound: 11, Bis-POM-PMEA	Cytotoxicity against mock-infected human CEM cells assessed as growth inhibition Cytotoxicity against mock-infected human CEM cells assessed as growth inhibition	[PMID: 23603046]
CCRF-CEM	EC₅₀	0.045 μM Compound: 11, Bis-POM-PMEA	Antiviral activity against wild type HIV-1 3B infected in human CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis Antiviral activity against wild type HIV-1 3B infected in human CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis	[PMID: 23603046]
CCRF-CEM	EC₅₀	0.062 μM Compound: 11, Bis-POM-PMEA	Antiviral activity against wild type HIV-2 ROD infected in human CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis Antiviral activity against wild type HIV-2 ROD infected in human CEM cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis	[PMID: 23603046]
CEM-SS	CC₅₀	4.4 μM Compound: 3	Compound was tested for antiviral activity against the CEM-SS cell lines infected with HIV-1. Compound was tested for antiviral activity against the CEM-SS cell lines infected with HIV-1.	[PMID: 8960556]
CEM-SS	EC₅₀	0.04 μM Compound: 3	Compound was tested for antiviral activity against the CEM-SS cell lines infected with HIV-1. Compound was tested for antiviral activity against the CEM-SS cell lines infected with HIV-1.	[PMID: 8960556]
HEK293	IC₅₀	13.5 μM Compound: ADV	Inhibition of human OAT1 expressed in HEK293 cells assessed as P-amino hippuric acid uptake inhibition incubated for 10 mins by UPLC-MS/MS method Inhibition of human OAT1 expressed in HEK293 cells assessed as P-amino hippuric acid uptake inhibition incubated for 10 mins by UPLC-MS/MS method	[PMID: 31301948]
HEL	EC₅₀	0.2 μM Compound: 11, Bis-POM-PMEA	Antiviral activity against Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis Antiviral activity against Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis	[PMID: 23603046]
HEL	EC₅₀	0.2 μM Compound: 11, Bis-POM-PMEA	Antiviral activity against Human simplex virus 2 G infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis Antiviral activity against Human simplex virus 2 G infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis	[PMID: 23603046]
HEL	EC₅₀	0.2 μM Compound: 11, Bis-POM-PMEA	Antiviral activity against thymidine kinase-deficient Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis Antiviral activity against thymidine kinase-deficient Human simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis	[PMID: 23603046]
HEL	EC₅₀	4 μM Compound: 11, Bis-POM-PMEA	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathicity measured at day 3 by microscopic analysis	[PMID: 23603046]
HepG2 2.2.15	CC₅₀	555 μM Compound: 2	Cytotoxicity against human HepG2(2.2.15) cells Cytotoxicity against human HepG2(2.2.15) cells	[PMID: 19889538]
HepG2 2.2.15	IC₅₀	0.33 μM Compound: 2	Antiviral activity against Hepatitis B virus infected HepG2(2.2.15) cells assessed as inhibition of viral cytoplasmic DNA synthesis by real-time PCR Antiviral activity against Hepatitis B virus infected HepG2(2.2.15) cells assessed as inhibition of viral cytoplasmic DNA synthesis by real-time PCR	[PMID: 19889538]
HepG2 2.2.15	EC₅₀	1.5 μM Compound: ADV	Antiviral activity against wild type HBV infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against wild type HBV infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	EC₅₀	1.8 μM Compound: ADV	Antiviral activity against 3TC-resistant HBV with polymerase M204V mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against 3TC-resistant HBV with polymerase M204V mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	EC₅₀	2 μM Compound: ADV	Antiviral activity against 3TC-resistant HBV with polymerase M204I mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against 3TC-resistant HBV with polymerase M204I mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	EC₅₀	2.1 μM Compound: ADV	Antiviral activity against 3TC-resistant HBV with polymerase L180M mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against 3TC-resistant HBV with polymerase L180M mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	EC₅₀	2.2 μM Compound: ADV	Antiviral activity against 3TC-resistant HBV with polymerase LMMV mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against 3TC-resistant HBV with polymerase LMMV mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	EC₅₀	7.5 μM Compound: ADV	Antiviral activity against ADV-resistant HBV N236T mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization Antiviral activity against ADV-resistant HBV N236T mutation infected in HepG2.2.15 cells assessed as nucleic acid and protein levels dosed daily for 9 days and measured 24 hrs after last treatment by Southern blot hybridization	[PMID: 20117930]
HepG2 2.2.15	CC₅₀	471.1 μM Compound: 1	Cytotoxicity against human HepG2(2.2.15) cells infected with HBV DNA Cytotoxicity against human HepG2(2.2.15) cells infected with HBV DNA	[PMID: 22305613]
HepG2 2.2.15	EC₅₀	0.96 μM Compound: 1	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication incubated for 2 days followed by wash out measured after 10 days by RT-PCR analysis Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication incubated for 2 days followed by wash out measured after 10 days by RT-PCR analysis	[PMID: 22305613]
HepG2 2.2.15	CC₅₀	>400 μM Compound: ADV	Toxicity against human HepG2.2.15 cells infected with HBV after 72 hrs by MTT assay Toxicity against human HepG2.2.15 cells infected with HBV after 72 hrs by MTT assay	[PMID: 27458783]
HepG2 2.2.15	CC₅₀	438.92 μM Compound: ADV	Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 12 hrs followed by replacement of fresh medium containing compound and measured after 2 days by CCK-8 assay Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability incubated for 12 hrs followed by replacement of fresh medium containing compound and measured after 2 days by CCK-8 assay	[PMID: 31301948]
HepG2 2.2.15	IC₅₀	0.48 μM Compound: ADV	Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as viral DNA level after 9 days by southern blot analysis Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as viral DNA level after 9 days by southern blot analysis	10.1007/s00044-011-9616-2
HepG2 2.2.15	IC₅₀	0.48 μmol Compound: ADV	Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as viral DNA level after 9 days by southern blot analysis Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as viral DNA level after 9 days by southern blot analysis	10.1007/s00044-011-9616-2
HepG2 2.2.15	IC₅₀	0.58 μM Compound: ADV	Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 9 days by RT-PCR analysis Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 9 days by RT-PCR analysis	10.1007/s00044-011-9616-2
HepG2 2.2.15	IC₅₀	0.58 μmol Compound: ADV	Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 9 days by RT-PCR analysis Antiviral activity against Hepatitis B virus infected human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication after 9 days by RT-PCR analysis	10.1007/s00044-011-9616-2
HK-2	CC₅₀	488.05 μM Compound: 1	Cytotoxicity against human HK2 cells by MTT assay Cytotoxicity against human HK2 cells by MTT assay	[PMID: 22305613]
Huh-7	CC₅₀	365 μM Compound: adefovir, adefovir dipivoxil, ADV	Effect on cell viability in human Huh7 cells Effect on cell viability in human Huh7 cells	[PMID: 17371827]
Huh-7	EC₅₀	13 μM Compound: adefovir, adefovir dipivoxil, ADV	Inhibition of wild type HBV replication in Huh7 cells Inhibition of wild type HBV replication in Huh7 cells	[PMID: 17371827]
Huh-7	EC₅₀	1.5 μM Compound: Adefovir dipivoxil	Antiviral activity against HBV harboring RNA polymerase M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against HBV harboring RNA polymerase M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Huh-7	EC₅₀	14 μM Compound: Adefovir dipivoxil	Antiviral activity against HBV harboring RNA polymerase N236T mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against HBV harboring RNA polymerase N236T mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Huh-7	EC₅₀	2 μM Compound: Adefovir dipivoxil	Antiviral activity against wild type HBV infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against wild type HBV infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Huh-7	EC₅₀	2.4 μM Compound: Adefovir dipivoxil	Antiviral activity against HBV harboring RNA polymerase M204I mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against HBV harboring RNA polymerase M204I mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Huh-7	EC₅₀	2.5 μM Compound: Adefovir dipivoxil	Antiviral activity against HBV harboring RNA polymerase L180M/M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against HBV harboring RNA polymerase L180M/M204V mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Huh-7	EC₅₀	2.6 μM Compound: Adefovir dipivoxil	Antiviral activity against HBV harboring RNA polymerase L180M mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs Antiviral activity against HBV harboring RNA polymerase L180M mutant gene infected in human HuH7 cells assessed as decrease in viral transient transfection after 24 hrs	[PMID: 19398648]
Huh-7	CC₅₀	>25 μM Compound: 11, Bis-POM-PMEA	Cytotoxicity against human HuH7 cells assessed as reduction of cell density Cytotoxicity against human HuH7 cells assessed as reduction of cell density	[PMID: 23603046]
Huh-7	EC₅₀	0.83 μM Compound: 11, Bis-POM-PMEA	Antiviral activity against wild type HBV transfected in human HuH7 cells assessed as reduction of viral DNA level after 7 days by qPCR analysis Antiviral activity against wild type HBV transfected in human HuH7 cells assessed as reduction of viral DNA level after 7 days by qPCR analysis	[PMID: 23603046]
MRC5	CC₅₀	15.7 μM Compound: 3	Compound was tested for antiviral activity against the MRC-5 cells infected with HSV-1. Compound was tested for antiviral activity against the MRC-5 cells infected with HSV-1.	[PMID: 8960556]
MRC5	EC₅₀	0.91 μM Compound: 3	Compound was tested for antiviral activity against the MRC-5 cells infected with HSV-2. Compound was tested for antiviral activity against the MRC-5 cells infected with HSV-2.	[PMID: 8960556]
MRC5	EC₅₀	1.23 μM Compound: 3	Compound was tested for antiviral activity against the MRC-5 cells infected with HSV-1. Compound was tested for antiviral activity against the MRC-5 cells infected with HSV-1.	[PMID: 8960556]
MT4	CC₅₀	0.74 μM Compound: 3	Compound was tested for antiviral activity against the MT-4 cell lines infected with HIV-1. Compound was tested for antiviral activity against the MT-4 cell lines infected with HIV-1.	[PMID: 8960556]
MT4	EC₅₀	0.08 μM Compound: 3	Compound was tested for antiviral activity against the MT-4 cell lines infected with HIV-1. Compound was tested for antiviral activity against the MT-4 cell lines infected with HIV-1.	[PMID: 8960556]
Vero	IC₅₀	0.6 μM Compound: 10a	Concentration that reduced plaque formation by 50% was measured in HSV-2 infected vero cells in vitro Concentration that reduced plaque formation by 50% was measured in HSV-2 infected vero cells in vitro	[PMID: 8021925]
Vero	CC₅₀	22.56 μM Compound: 3	Compound was tested for antiviral activity against the Vero cells infected with HSV-1. Compound was tested for antiviral activity against the Vero cells infected with HSV-1.	[PMID: 8960556]
Vero	EC₅₀	0.87 μM Compound: 3	Compound was tested for antiviral activity against the Vero cells infected with HSV-1. Compound was tested for antiviral activity against the Vero cells infected with HSV-1.	[PMID: 8960556]
Vero	EC₅₀	1.15 μM Compound: 3	Compound was tested for antiviral activity against the Vero cells infected with HSV-2 Compound was tested for antiviral activity against the Vero cells infected with HSV-2	[PMID: 8960556]
WI-38	CC₅₀	3.1 μM Compound: PMEA dipivoxil	Cytotoxicity against human WI38 cells by neutral red assay Cytotoxicity against human WI38 cells by neutral red assay	[PMID: 18285481]
WI-38	EC₅₀	0.7 μM Compound: PMEA dipivoxil	Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis	[PMID: 18285481]

In Vitro

Adefovir dipivoxil (0.03-30 μM; 6 days) significantly inhibits the proliferation of H1975, A549 and PC9 cells, with more pronounced inhibition when co-treated with VE822^[1].
Adefovir dipivoxil (1 μM; 3 days) exhibits increased basolateral-to-apical transport and an elevated efflux ratio in Caco-2 cells treated with 1,25(OH)₂D₃^[2].
Adefovir dipivoxil (24 h) can effectively inhibit PRV proliferation in PK-15 cells, with an IC₅₀ of 92.39 nM^[4].
Adefovir dipivoxil (1-10 μM) sensitizes colon cancer cells (HCT116-CDK1 and HT29-CDK1 cells) to Vemurafenib (HY-12057) by disrupting KCTD12-CDK1 interaction^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Western Blot Analysis^[1]

View Protocol

Cell Line:

H1975
Concentration:

0.1, 1, 3, 10, 30 μM
Incubation Time:

24 h
Result:

Activated the ATR signaling pathway.
Resulted in changes in the levels of cell cycle protein F, phosphorylated CDK2, RRM2, phosphorylated RPA, γH2AX, and other related proteins as a result of co-treatment with VE822.

In Vivo

Adefovir dipivoxil (5 mg/kg; i.p.; once a day, 5 days) can potently protect mice against lethal PRV infection, as shown by reduced pathological lesions, lower viral particles in major organs, and increased survival rate^[4].
Adefovir dipivoxil (10-50 mg/kg; p.o.; every other day) inhibits the growth of colon cancer cell-derived tumor xenografts in BALB/c nude mice^[5].
Adefovir dipivoxil (100 mg/kg/day; p.o.; twice daily; 10 days) reduces viral load in the liver and serum in transgenic mice expressing hepatitis B virus (HBV)^[6].
Adefovir dipivoxil (250 mg prodrug per dog for suspension; p.o.; single dose) shows oral bioavailability of 35.0% (suspension) in beagle dogs^[7].
Adefovir dipivoxil (30 mg/kg; every other day; 21 days) causes a marked reduction of duck HBV (DHBV) DNA in serum in congenitally HBV-infected ducklings^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Transgenic mice expressing HBV^[6]
Dosage:

100 mg/kg/day
Administration:

Oral gavage, twice daily for 10 days; once daily for 10-21 days
Result:

Reduced liver HBV DNA to near the levels of detection (0.02 pg viral DNA/g cellular DNA) at 100 mg/kg/day twice daily.
Had significant antiviral effects on serum HBV DNA on days 4, 7, 10, and 21 when administered once daily at a dose of 100 mg/kg/day.
Was effective in significantly reducing liver HBV DNA with once-daily treatment at doses as low as 1.0 mg/kg/day.
Had no significant effect on core antigen (HBcAg) in the liver or pre-core antigen (HBeAg) in the serum, and did not significantly reduce liver HBV RNA.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 142340-99-6
Appearance Solid
Masse moléculaire 501.47
Formule C₂₀H₃₂N₅O₈P
Color White to off-white
SMILES

NC1=C2N=CN(CCOCP(OCOC(C(C)(C)C)=O)(OCOC(C(C)(C)C)=O)=O)C2=NC=N1
Synonyms

GS 0840
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (2)

All

Sort by:

Journal Impact Factor

Int J Mol Med

Brca1 is involved in tolerance to adefovir dipivoxil‑induced DNA damage. [Abstract]

2019 Jun;43(6):2491-2498. PMID: 31017265
PLoS Pathog

Anti-orthopoxvirus drugs inhibit lumpy skin disease virus replication by targeting viral DNA polymerase. [Abstract]

2026 Jan 26;22(1):e1013903. PMID: 41587213

Solvant et solubilité

In Vitro:

DMSO : ≥ 100 mg/mL (199.41 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 0.67 mg/mL (1.34 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9941 mL

9.9707 mL

19.9414 mL

5 mM

0.3988 mL

1.9941 mL

3.9883 mL

10 mM

0.1994 mL

0.9971 mL

1.9941 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

All Cell Biology Signal Pathway Related Animals and Diseases

EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (295 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Patel A, et al. Adefovir dipivoxil induces DNA replication stress and augments ATR inhibitor-related cytotoxicity. Int J Cancer. 2020 Sep 1;147(5):1474-1484. [Content Brief]

[2]. Maeng HJ, et al. Effects of 1α,25-dihydroxyvitamin D3 on transport and metabolism of adefovir dipivoxil and its metabolites in Caco-2 cells. Eur J Pharm Sci. 2012 Jun 14;46(3):149-66. [Content Brief]

[3]. Annaert P, et al. In vitro, ex vivo, and in situ intestinal absorption characteristics of the antiviral ester prodrug adefovir dipivoxil. J Pharm Sci. 2000 Aug;89(8):1054-62. [Content Brief]

[4]. Wang G, et al. Adefovir dipivoxil efficiently inhibits the proliferation of pseudorabies virus in vitro and in vivo. Antiviral Res. 2021 Feb;186:105014. [Content Brief]

[5]. Yang J, et al. Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction. Cancer Lett. 2019 Jun 1;451:79-91. [Content Brief]

[6]. Julander JG, et al. Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Res. 2002 Jul;55(1):27-40. [Content Brief]

[7]. Cundy KC, et al. Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs. J Pharm Sci. 1997 Dec;86(12):1334-8. [Content Brief]

[8]. Qaqish RB, et al. Adefovir dipivoxil: a new antiviral agent for the treatment of hepatitis B virus infection. Clin Ther. 2003 Dec;25(12):3084-99. [Content Brief]

[9]. Buti M, et al. Adefovir dipivoxil. Drugs Today (Barc). 2003;39(2):127-135. [Content Brief]

[10]. Mark N Prichard, et al. Orthopoxvirus targets for the development of antiviral therapies. Curr Drug Targets Infect Disord. 2005 Mar;5(1):17-28. [Content Brief]

[11]. Noble S, et al. Adefovir dipivoxil. Drugs. 1999;58(3):479-489. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	1.9941 mL	9.9707 mL	19.9414 mL	49.8534 mL
DMSO	5 mM	0.3988 mL	1.9941 mL	3.9883 mL	9.9707 mL
	10 mM	0.1994 mL	0.9971 mL	1.9941 mL	4.9853 mL
	15 mM	0.1329 mL	0.6647 mL	1.3294 mL	3.3236 mL
	20 mM	0.0997 mL	0.4985 mL	0.9971 mL	2.4927 mL
	25 mM	0.0798 mL	0.3988 mL	0.7977 mL	1.9941 mL
	30 mM	0.0665 mL	0.3324 mL	0.6647 mL	1.6618 mL
	40 mM	0.0499 mL	0.2493 mL	0.4985 mL	1.2463 mL
	50 mM	0.0399 mL	0.1994 mL	0.3988 mL	0.9971 mL
	60 mM	0.0332 mL	0.1662 mL	0.3324 mL	0.8309 mL
	80 mM	0.0249 mL	0.1246 mL	0.2493 mL	0.6232 mL
	100 mM	0.0199 mL	0.0997 mL	0.1994 mL	0.4985 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Bioz

Adefovir dipivoxil

2 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Adefovir dipivoxil

Publications Citing Use of MedChemExpress (MCE) Adefovir dipivoxil

Voir tous les produits spécifiques à Isoform HSV

Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis

Voir tous les produits spécifiques à Isoform ATM/ATR

Voir tous les produits spécifiques à Isoform CDK